Selected Publications

Federman N, Drilon A, Toledano H, Albert CM, Doz F, Xu RH, Geoerger B, Mascarenhas L, Qi C, Dierselhuis MP, Burcoveanu DI, Brega N, Neu N, van Tilburg C, Laetsch TW, Hong DS: Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Cancer Who Achieved Complete Response. European Society for Medical Oncology (ESMO) Annual Meeting, Berlin Germany - Poster Presentation Oct 2025.

Blattmann C, Mascarenhas L, Orbach D, Federman N, DuBois S G, Albert CM, Pappo A, Zwaan CM, Burcoveanu DI, Neu N, De La Cuesta E, Laetsch TW, van Tilburg CM : Treatment discontinuation outcomes in paediatric patients with TRK fusion sarcomas treated with larotrectinib. European Society for Medical Oncology (ESMO) Annual Meeting, Berlin Germany - Podium Presentation Oct 2025.

Trent J, Wang H, Watt T, Choi W, Schilling F, Glade Bender J, Kasenda B, Tabatabai G, Burcoveanu DI, Neu N, Carrasco CP, Hong DS, Laetsch TW: Real-world study of larotrectinib in patients with TRK fusion solid tumours: interim analysis of ON-TRK. European Society for Medical Oncology (ESMO) Annual Meeting, Berlin Germany - Podium Presentation Oct 2025.

Valero-Arrese L, Doz F, Nysom K, Sjöberg Bexelius T, Idbaih A, Geoerger B, Kebudi R, Burcoveanu DI, Neu N, Brega N, Drilon A, Laetsch TW, van Tilburg C, Perreault S: Long-term efficacy and safety of larotrectinib inTRK fusion primary central nervous system tumours: an updated analysis. European Society for Medical Oncology (ESMO) Annual Meeting, Berlin Germany - Podium Presentation Oct 2025.

Hong DS, Doz F, Xu RH, Qi C, Albert CM, DuBois SG, Federman N, Lin JJ, Toledano H, Brose MS, Casanova M, Burcoveanu DI, Brega N, Neu N, Laetsch TW, van Tilburg CM, Drilon A: Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Cancer Who Had a Long-Term Response. European Society for Medical Oncology (ESMO) Annual Meeting, Berlin Germany - Poster Presentation Oct 2025.

Vasta LM, Chen KS, Hicks J, Rudzinski ER, Parbhoo K, Shern J, Jagu S, Reaman G, Smith M, Cottrell C, Hawkins DS, Schultz KAP, Laetsch TW: Analyzing Impact of CCDI COG Molecular Characterization Initiative (MCI) on Rare Tumors. Child Cancer Data Initiative (CCDI) Symposium, Washington DC - Poster Presentation Oct 2025.

Naik S, Selukar S, Talleur AC, Deshpande S, Llaurador Caraballo G, Fabrizio VA, Rouce RH, Zeng XL, Vatsayan A, Rossoff J, Pacenta HL, John S, Phillips CL, Talano JA, Moskop A, Verneris MR, Myers GD, Hall E, Karras N, Bonifant CL, Qayed M, Bakinowski E, Keating AK, Baumeister SHC, Tomilson E, Hermiston ML, Satwani P, Krupski C, Chinnabhandar V, Stefanski HE, Egeler E, Curran KJ, Laetsch TW, Mackall CL, Prabhu S, Nguyen KP, Baggott C, Schultz LM, McNerney KO: Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Advances Oct 2025 Notes: DOI: 10.1182/bloodadvances.2025016824.

Mehrhoff C, Dagalakis U, Bauer AJ, Mahajan P, Laetsch TW, Mostoufi-Moab S: Navigating Multidisciplinary Care in Pediatric Thyroid Carcinoma: Insights From Children's Oncology Group Sites. Pediatric Blood Cancer Oct 2025 Notes: DOI: 10.1002/pbc.31919.

Campbell ME, Stutzman S, Primeaux S, Sida D, Lee M, Shah AT, Sadanand A, Sokol E, Collins NB, Turpin B, Navai S, Albert K, Laetsch TW, Rakheja D, Chen KS, Gerber DE, Koh AY: Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatric Blood Cancer Sep 2025 Notes: DOI: 10.1002/pbc.32046.

Appell LE, Baggott C, Nguyen K, Prabhu S, Pacenta HL, John S, Fabrizio VA, Phillips CL, Rossoff J, Talano JM, Moskop A, Phelan R, Baumeister SHC, Verneris MR, Hall EM, Myers GD, Karras NA, Cooper S, Qayed M, Raikar SS, Winestone LE, Hermiston ML, Satwani P, Krupski C, Keating A, Friedman DN, Curran KJ, Hoover A, MacMillan ML, Ebens CL, Ramgopal A, Rahrig AL, Mackall CL, Laetsch TW, Schultz LM: Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel. Blood Advances Sep 2025 Notes: DOI: 10.1182/bloodadvances.2025017012.